Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations (MAKP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study is to identify genetic abnormalities and molecular pathways associated with the occurrence of CCAM.
| Condition | Intervention |
|---|---|
|
Congenital Cystic Adenomatoid Malformation (CCAM) |
Genetic: Patient |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations |
- mRNA expression [ Time Frame: at Day 0 ] [ Designated as safety issue: No ]Transcriptomic analysis
- Protein expression [ Time Frame: at Day 0 ] [ Designated as safety issue: No ]Proteomic expression
- Somatic genetic abnormalities [ Time Frame: at Day 0 ] [ Designated as safety issue: No ]CGH array
| Estimated Enrollment: | 70 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | October 2015 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Patient
Cohort of patients
|
Genetic: Patient
Blood and histological samples will be done at day of the inclusion.
|
Detailed Description:
Congenital lung malformations are rare diseases, characterized by the coexistence in the same individual of normal lung and localized lung malformation. Among these malformations, congenital cystic adenomatoid malformations (CCAM) represent the most important group, with an estimated incidence between 1/11 000 and 1/35 000 births. The precise mechanisms leading to these lung malformations remain poorly understood. This project aims to identify key genetic and/or molecular mechanisms associated with the occurrence of CCAM. CCAMs are collected during postnatal surgical resection. Parental agreement is required. A standardised histologic description of malformations is performed for each sample. Normal lung tissue at the periphery of the malformation is considered as control. Malformations will be analyzed in a systematic way by proteome and transcriptome, after laser microdissection. Somatic genetic abnormalities will also systematically be sought.
Eligibility| Ages Eligible for Study: | up to 8 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children < 8 years
- Thoracic surgery for congenital lung malformation
- Parental written consent
Exclusion Criteria:
- Children > 8 years
- Previous infection of the malformation
- Parental rebutal
Contacts and Locations| Contact: Christophe Delacourt, MD, PhD | + 33 1 44 49 49 55 | christophe.delacourt@nck.aphp.fr |
| Contact: Laurence Lecomte, PhD | +33 1 71 19 64 94 | laurence.lecomte@nck.aphp.fr |
| France | |
| Necker-Enfants Malades Hospital | Recruiting |
| Paris, France, 75015 | |
| Contact: Christophe Delacourt, MD, PhD + 33 1 44 49 49 55 christophe.delacourt@nck.aphp.fr | |
| Principal Investigator: | Christophe Delacourt, MD, PhD | Necker-Enfants Malades Hospital |
More Information
Publications:
| Responsible Party: | Assistance Publique - Hôpitaux de Paris |
| ClinicalTrials.gov Identifier: | NCT01732185 History of Changes |
| Other Study ID Numbers: | P100510 |
| Study First Received: | November 19, 2012 |
| Last Updated: | November 19, 2012 |
| Health Authority: | France: Ministry of Health |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
Congenital lung malformation Congenital Cystic Adenomatoid Malformation Cystic lung disease |
Additional relevant MeSH terms:
|
Congenital Abnormalities Cystic Adenomatoid Malformation of Lung, Congenital Lung Diseases Respiratory Tract Diseases Respiratory System Abnormalities |
ClinicalTrials.gov processed this record on May 16, 2013